uric acid has been researched along with Hip Fractures in 12 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Hip Fractures: Fractures of the FEMUR HEAD; the FEMUR NECK; (FEMORAL NECK FRACTURES); the trochanters; or the inter- or subtrochanteric region. Excludes fractures of the acetabulum and fractures of the femoral shaft below the subtrochanteric region (FEMORAL FRACTURES).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Uric acid has been shown to provide a neuroprotective effect in various neurodegenerative diseases through its antioxidant properties." | 5.72 | Lower preoperative serum uric acid level may be a risk factor for postoperative delirium in older patients undergoing hip fracture surgery: a matched retrospective case-control study. ( Li, C; Li, J; Lyu, W; Wei, P; Xu, L; Zhang, Z; Zheng, Q, 2022) |
| "Hip fractures were not significantly associated with UA." | 5.40 | Association of serum uric acid and incident nonspine fractures in elderly men: the Osteoporotic Fractures in Men (MrOS) study. ( Cawthon, PM; Lane, NE; Lay, YA; Lui, LY; Orwoll, E; Parimi, N; Wise, BL; Yao, W, 2014) |
| "Patients with hyperuricemia or gout or patients with high and low levels of serum uric acid may face poor outcomes of hip fractures." | 4.12 | The paradoxical relation between serum uric acid and outcomes of hip fracture in older patients after surgery: A 1-year follow-up study. ( Chu, Q; Fu, M; Liu, M; Sun, G; Wang, J; Yang, C; Zhang, Z, 2022) |
| "Using a Danish Register cohort of 86,039 adult new allopurinol users and propensity score matched controls, we found that gout requiring allopurinol prescription was associated with an increased fracture risk." | 3.81 | Is allopurinol use associated with an excess risk of osteoporotic fracture? A National Prescription Registry study. ( Abrahamsen, B; Bone, KW; Cooper, C; Dennison, EM; Harvey, NC; Rubin, KH; Schwarz, P, 2015) |
| "Gout is associated with a higher risk of fracture; however, findings on the associations of hyperuricemia and urate-lowering therapy (ULT) with the risk of fracture have been inconsistent." | 1.91 | Lowering Serum Urate With Urate-Lowering Therapy to Target and Incident Fracture Among People With Gout. ( Choi, HK; Dalbeth, N; Lane, NE; Lei, G; Lyu, H; Wei, J; Wu, J; Zeng, C; Zhang, Y, 2023) |
| "Uric acid has been shown to provide a neuroprotective effect in various neurodegenerative diseases through its antioxidant properties." | 1.72 | Lower preoperative serum uric acid level may be a risk factor for postoperative delirium in older patients undergoing hip fracture surgery: a matched retrospective case-control study. ( Li, C; Li, J; Lyu, W; Wei, P; Xu, L; Zhang, Z; Zheng, Q, 2022) |
| "Hip fractures were not significantly associated with UA." | 1.40 | Association of serum uric acid and incident nonspine fractures in elderly men: the Osteoporotic Fractures in Men (MrOS) study. ( Cawthon, PM; Lane, NE; Lay, YA; Lui, LY; Orwoll, E; Parimi, N; Wise, BL; Yao, W, 2014) |
| "Furthermore, congestive heart failure is associated with impaired creatinine clearance and increased urea and urate, and osteoporosis and hip fractures are characterized by low albumin and cholesterol." | 1.32 | Association of biochemical values with morbidity in the elderly: a population-based Swedish study of persons aged 82 or more years. ( Berg, S; Evrin, PE; Johansson, B; McClearn, G; Nilsson, SE; Takkinen, S; Tryding, N, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 6 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, M | 1 |
| Chu, Q | 1 |
| Yang, C | 1 |
| Wang, J | 1 |
| Fu, M | 1 |
| Zhang, Z | 2 |
| Sun, G | 1 |
| Xu, L | 1 |
| Lyu, W | 1 |
| Wei, P | 1 |
| Zheng, Q | 1 |
| Li, C | 1 |
| Li, J | 1 |
| Wei, J | 1 |
| Choi, HK | 1 |
| Dalbeth, N | 1 |
| Lane, NE | 2 |
| Wu, J | 1 |
| Lyu, H | 1 |
| Zeng, C | 1 |
| Lei, G | 1 |
| Zhang, Y | 1 |
| Preyer, O | 2 |
| Concin, H | 2 |
| Nagel, G | 2 |
| Zitt, E | 2 |
| Ulmer, H | 2 |
| Brozek, W | 2 |
| Lai, SW | 1 |
| Kuo, YH | 1 |
| Liao, KF | 1 |
| Parimi, N | 1 |
| Lui, LY | 1 |
| Wise, BL | 1 |
| Yao, W | 1 |
| Lay, YA | 1 |
| Cawthon, PM | 1 |
| Orwoll, E | 1 |
| Mehta, T | 1 |
| Bůžková, P | 1 |
| Sarnak, MJ | 1 |
| Chonchol, M | 1 |
| Cauley, JA | 1 |
| Wallace, E | 1 |
| Fink, HA | 1 |
| Robbins, J | 1 |
| Jalal, D | 1 |
| Dennison, EM | 1 |
| Rubin, KH | 1 |
| Schwarz, P | 1 |
| Harvey, NC | 1 |
| Bone, KW | 1 |
| Cooper, C | 1 |
| Abrahamsen, B | 1 |
| Muka, T | 1 |
| de Jonge, EA | 1 |
| Kiefte-de Jong, JC | 1 |
| Uitterlinden, AG | 1 |
| Hofman, A | 1 |
| Dehghan, A | 1 |
| Zillikens, MC | 1 |
| Franco, OH | 1 |
| Rivadeneira, F | 1 |
| Nilsson, SE | 1 |
| Takkinen, S | 1 |
| Tryding, N | 1 |
| Evrin, PE | 1 |
| Berg, S | 1 |
| McClearn, G | 1 |
| Johansson, B | 1 |
| Maesaka, JK | 1 |
| Miyawaki, N | 1 |
| Palaia, T | 1 |
| Fishbane, S | 1 |
| Durham, JH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Postprandial Hyperglycemia on the Arterial Stiffness in Patients With Type 2 Diabetes[NCT01159938] | Phase 4 | 72 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Changes in BG from the baseline [30-minute (min) pre-breakfast] are reported. (NCT01159938)
Timeframe: 30 mins (pre-breakfast), 50, 110 ,170, and 230 mins (post-breakfast)
| Intervention | millimoles per liter (mmol/L) (Mean) | |||
|---|---|---|---|---|
| 50-Min Post-Breakfast (n=24, 21, 22, 24, 24) | 110-Min Post-Breakfast (n= 25, 21, 22, 24, 24) | 170-Min Post-Breakfast (n= 25, 21, 22, 24, 24) | 230-Min Post-Breakfast (n= 25, 21, 22, 24, 24) | |
| Healthy Participants | 0.07 | -0.15 | -0.36 | -0.54 |
| T2DM With Albuminuria (High Postprandial Glucose) | 4.98 | 4.73 | 3.14 | 1.78 |
| T2DM With Albuminuria (Low Postprandial Glucose) | 3.39 | 2.52 | 0.29 | -0.92 |
| T2DM With Normal UAER (High Postprandial Glucose) | 5.59 | 5.58 | 3.65 | 1.79 |
| T2DM With Normal UAER (Low Postprandial Glucose) | 3.23 | 2.59 | 1.26 | -0.13 |
The PAT device is a pneumatic plethysmograph that applies uniform pressure to the surface of each finger tip and measures digital pulse amplitude. The PAT was reported as a percentage of pulse amplitude and expressed as the ratio of post deflation to baseline pulse amplitude in hyperemic finger divided by the same ratio in the contralateral finger that served as a control. The change in PAT from baseline [30-minute (min) pre-breakfast] is reported. (NCT01159938)
Timeframe: 30 mins (pre-breakfast), 120 and 240 mins (post-breakfast)
| Intervention | percentage of pulse amplitude (Mean) | |
|---|---|---|
| 120-Min Post-Breakfast (n= 23, 20, 22, 23, 23) | 240-Min Post-Breakfast (n= 24, 21, 22, 23, 21) | |
| Healthy Participants | 0.03 | 0.15 |
| T2DM With Albuminuria (High Postprandial Glucose) | 0.09 | 0.23 |
| T2DM With Albuminuria (Low Postprandial Glucose) | 0.11 | 0.32 |
| T2DM With Normal UAER (High Postprandial Glucose) | 0.36 | 0.36 |
| T2DM With Normal UAER (Low Postprandial Glucose) | -0.05 | 0.24 |
The PWV measured arterial stiffness in the aortic and brachial arteries of healthy participants and T2DM participants. Changes in PWV from baseline [30-minute (min) pre-breakfast] are reported. (NCT01159938)
Timeframe: 30 mins (pre-breakfast), 60, 120, 180 and 240 mins (post-breakfast)
| Intervention | meters per second (m/sec) (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| 60-Min Post-Breakfast (Aortic;n=22,21,22,23,22) | 120-Min Post-Breakfast (Aortic;n=22,21,22,23,22) | 180-Min Post-Breakfast (Aortic;n=23,21,22,23,22) | 240-Min Post-Breakfast (Aortic;n=23,21,22,23,22) | 60-Min Post-Breakfast (Brachial;n=23,21,22,24,23) | 120-Min Post-Breakfast (Brachial;n=22,21,22,24,23) | 180-Min Post-Breakfast (Brachial;n=24,21,22,24,23) | 240-Min Post-Breakfast (Brachial;n=23,21,22,24,23) | |
| Healthy Participants | -0.26 | 0.25 | -0.00 | 0.99 | -0.13 | 0.23 | -0.37 | -0.10 |
| T2DM With Albuminuria (High Postprandial Glucose) | -0.74 | 0.04 | -0.32 | -0.09 | 0.23 | 0.09 | -0.06 | 0.17 |
| T2DM With Albuminuria (Low Postprandial Glucose) | -0.91 | -0.58 | 0.22 | 0.00 | 0.03 | 0.09 | 0.35 | 0.41 |
| T2DM With Normal UAER (High Postprandial Glucose) | -0.52 | 0.09 | 0.48 | 0.61 | 0.19 | 0.25 | 0.55 | 0.35 |
| T2DM With Normal UAER (Low Postprandial Glucose) | 0.22 | 0.75 | 0.94 | 1.65 | -0.06 | -0.04 | -0.23 | 0.23 |
The PWA measured systemic arterial stiffness (augmentation index). PWA was reported as a percentage of systolic peak and calculated as the difference between second and first systolic peak in an ascending aortic pulse pressure waveform divided by the first systolic peak then multiplied by 100. The change in PWA from baseline [30-minute (min) pre-breakfast] is reported. (NCT01159938)
Timeframe: 30 mins (pre-breakfast), 60, 120, 180 and 240 mins (post-breakfast)
| Intervention | percentage of systolic peak (Mean) | |||
|---|---|---|---|---|
| 60-Min Post-Breakfast | 120-Min Post-Breakfast | 180-Min Post-Breakfast | 240-Min Post-Breakfast | |
| Healthy Participants | -4.4 | -2.9 | -1.9 | 2.1 |
| T2DM With Albuminuria (High Postprandial Glucose) | -4.1 | -3.7 | -2.3 | -2.2 |
| T2DM With Albuminuria (Low Postprandial Glucose) | -0.6 | -1.7 | -0.5 | 0.6 |
| T2DM With Normal UAER (High Postprandial Glucose) | -2.3 | -2.9 | 1.0 | -0.7 |
| T2DM With Normal UAER (Low Postprandial Glucose) | -2.5 | -2.3 | -1.1 | -0.6 |
QT interval is a measure of time from the beginning of the QRS complex to the end of the T wave on an ECG during which contraction of the ventricles occurs. Changes in QT interval from baseline [30-minute (min) pre-breakfast] are reported. (NCT01159938)
Timeframe: 30 mins (pre-breakfast), 60, 120, 180 and 240 mins (post-breakfast)
| Intervention | milliseconds (msec) (Mean) | |||
|---|---|---|---|---|
| 60-Min Post-Breakfast (n=25, 20, 21, 24, 24) | 120-Min Post-Breakfast (n=25, 21, 21, 24, 24) | 180-Min Post-Breakfast (n=25, 21, 21, 23 ,24) | 240-Min Post-Breakfast (n=25, 21, 21, 24, 24) | |
| Healthy Participants | 12.1 | -0.4 | 8.3 | 10.4 |
| T2DM With Albuminuria (High Postprandial Glucose) | 23.8 | 18.0 | 19.1 | 18.5 |
| T2DM With Albuminuria (Low Postprandial Glucose) | 6.5 | -0.8 | 5.8 | 7.2 |
| T2DM With Normal UAER (High Postprandial Glucose) | 11.0 | 1.4 | 2.5 | 5.0 |
| T2DM With Normal UAER (Low Postprandial Glucose) | 11.3 | 2.8 | 4.5 | 5.6 |
The PWV measured arterial stiffness in the aortic and brachial arteries of T2DM participants. The Least Square (LS) mean was estimated from a mixed-effect analysis of covariance (ANCOVA) model that was adjusted for age, body mass index (BMI), visit, group, condition, group by condition, and random participant. (NCT01159938)
Timeframe: 120 mins (post-breakfast)
| Intervention | meters per second (m/sec) (Least Squares Mean) | |
|---|---|---|
| Aortic PWV (n=45, 44, 21, 22, 24, 22) | Brachial PWV (n=45, 45, 21, 22, 24, 23) | |
| T2DM Overall (High Postprandial Glucose) | 10.96 | 7.66 |
| T2DM Overall (Low Postprandial Glucose) | 10.76 | 7.86 |
| T2DM With Albuminuria (High Postprandial Glucose) | 11.18 | 7.84 |
| T2DM With Albuminuria (Low Postprandial Glucose) | 10.61 | 8.03 |
| T2DM With Normal UAER (High Postprandial Glucose) | 10.74 | 7.49 |
| T2DM With Normal UAER (Low Postprandial Glucose) | 10.92 | 7.70 |
The PWV measured arterial stiffness in the aortic and brachial arteries of T2DM participants. The Least Square (LS) mean was estimated from a mixed-effect analysis of covariance (ANCOVA) model that was adjusted for age, body mass index (BMI), visit, group, condition, group by condition, and random participant. (NCT01159938)
Timeframe: 180 mins (post-breakfast)
| Intervention | meters per second (m/sec) (Least Squares Mean) | |
|---|---|---|
| Aortic PWV (n= 45, 45, 21, 22, 24, 23) | Brachial PWV (n= 45, 45, 21, 22, 24, 23) | |
| T2DM Overall (High Postprandial Glucose) | 10.99 | 7.75 |
| T2DM Overall (Low Postprandial Glucose) | 11.28 | 7.91 |
| T2DM With Albuminuria (High Postprandial Glucose) | 11.04 | 7.75 |
| T2DM With Albuminuria (Low Postprandial Glucose) | 11.47 | 8.32 |
| T2DM With Normal UAER (High Postprandial Glucose) | 10.95 | 7.76 |
| T2DM With Normal UAER (Low Postprandial Glucose) | 11.09 | 7.50 |
The PWV measured arterial stiffness in the aortic and brachial arteries of T2DM participants. The Least Square (LS) mean was estimated from a mixed-effect analysis of covariance (ANCOVA) model that was adjusted for age, body mass index (BMI), visit, group, condition, group by condition, and random participant. (NCT01159938)
Timeframe: 240 mins (post-breakfast)
| Intervention | meters per second (m/sec) (Least Squares Mean) | |
|---|---|---|
| Aortic PWV (n= 45, 45, 21, 22, 24, 23) | Brachial PWV (n= 45, 45, 21, 22, 24, 23) | |
| T2DM Overall (High Postprandial Glucose) | 11.09 | 7.76 |
| T2DM Overall (Low Postprandial Glucose) | 11.57 | 8.16 |
| T2DM With Albuminuria (High Postprandial Glucose) | 10.99 | 7.99 |
| T2DM With Albuminuria (Low Postprandial Glucose) | 11.16 | 8.42 |
| T2DM With Normal UAER (High Postprandial Glucose) | 11.19 | 7.53 |
| T2DM With Normal UAER (Low Postprandial Glucose) | 11.98 | 7.90 |
The PWV measured arterial stiffness in the aortic and brachial arteries of T2DM participants. The Least Square (LS) mean was estimated from a mixed-effect analysis of covariance (ANCOVA) model that was adjusted for age, body mass index (BMI), visit, group, condition, group by condition, and random participant. (NCT01159938)
Timeframe: 30 mins (pre-breakfast)
| Intervention | meters per second (m/s) (Least Squares Mean) | |
|---|---|---|
| Aortic PWV (n=44, 44, 21, 22, 23, 22) | Brachial PWV (n=45, 45, 21, 22, 24, 23) | |
| T2DM Overall (High Postprandial Glucose) | 10.99 | 7.49 |
| T2DM Overall (Low Postprandial Glucose) | 10.73 | 7.84 |
| T2DM With Albuminuria (High Postprandial Glucose) | 11.56 | 7.79 |
| T2DM With Albuminuria (Low Postprandial Glucose) | 11.31 | 7.99 |
| T2DM With Normal UAER (High Postprandial Glucose) | 10.41 | 7.19 |
| T2DM With Normal UAER (Low Postprandial Glucose) | 10.15 | 7.68 |
The PWV measured arterial stiffness in the aortic and brachial arteries of T2DM participants. The Least Square (LS) mean was estimated from a mixed-effect analysis of covariance (ANCOVA) model that was adjusted for age, body mass index (BMI), visit, group, condition, group by condition, and random participant. (NCT01159938)
Timeframe: 60 mins (post-breakfast)
| Intervention | meters per second (m/sec) (Least Squares Mean) | |
|---|---|---|
| Aortic PWV (n= 44, 45, 21, 22, 23, 23) | Brachial PWV (n=45, 45, 21, 22, 24, 23) | |
| T2DM Overall (High Postprandial Glucose) | 10.19 | 7.71 |
| T2DM Overall (Low Postprandial Glucose) | 10.38 | 7.80 |
| T2DM With Albuminuria (High Postprandial Glucose) | 10.26 | 8.03 |
| T2DM With Albuminuria (Low Postprandial Glucose) | 10.22 | 8.00 |
| T2DM With Normal UAER (High Postprandial Glucose) | 10.12 | 7.39 |
| T2DM With Normal UAER (Low Postprandial Glucose) | 10.53 | 7.61 |
12 other studies available for uric acid and Hip Fractures
| Article | Year |
|---|---|
The paradoxical relation between serum uric acid and outcomes of hip fracture in older patients after surgery: A 1-year follow-up study.
Topics: Aged; Female; Follow-Up Studies; Gout; Hip Fractures; Humans; Hyperuricemia; Male; Risk Factors; Uri | 2022 |
Lower preoperative serum uric acid level may be a risk factor for postoperative delirium in older patients undergoing hip fracture surgery: a matched retrospective case-control study.
Topics: Aged; Case-Control Studies; Delirium; Hip Fractures; Humans; Postoperative Complications; Retrospect | 2022 |
Lowering Serum Urate With Urate-Lowering Therapy to Target and Incident Fracture Among People With Gout.
Topics: Adult; Gout; Gout Suppressants; Hip Fractures; Humans; Hyperuricemia; Uric Acid | 2023 |
Serum uric acid is associated with incident hip fractures in women and men - Results from a large Austrian population-based cohort study.
Topics: Austria; Biomarkers; Cohort Studies; Female; Hip Fractures; Humans; Hyperuricemia; Incidence; Male; | 2021 |
Serum uric acid and the risk of incident hip fractures in women and men.
Topics: Accidental Falls; Bone Density; Female; Fractures, Bone; Hip Fractures; Humans; Incidence; Male; Ost | 2021 |
Response to comments on the paper "serum uric acid is associated with incident hip fractures in women and men".
Topics: Bone Density; Hip Fractures; Humans; Osteoporotic Fractures; Uric Acid | 2021 |
Association of serum uric acid and incident nonspine fractures in elderly men: the Osteoporotic Fractures in Men (MrOS) study.
Topics: Aged; Allopurinol; Bone Density; Cohort Studies; Gout; Hip Fractures; Humans; Incidence; Male; Osteo | 2014 |
Serum urate levels and the risk of hip fractures: data from the Cardiovascular Health Study.
Topics: Aged; Aged, 80 and over; Body Mass Index; Cohort Studies; Estrogen Replacement Therapy; Female; Heal | 2015 |
Is allopurinol use associated with an excess risk of osteoporotic fracture? A National Prescription Registry study.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Comorbidity; Denmark; Female; Gout; Gout Suppressants; | 2015 |
The Influence of Serum Uric Acid on Bone Mineral Density, Hip Geometry, and Fracture Risk: The Rotterdam Study.
Topics: Aged; Bone Density; Cohort Studies; Female; Femur Neck; Hip Fractures; Humans; Male; Middle Aged; Ne | 2016 |
Association of biochemical values with morbidity in the elderly: a population-based Swedish study of persons aged 82 or more years.
Topics: Aged; Aged, 80 and over; Biomarkers; Blood Chemical Analysis; Body Mass Index; Cholesterol; Creatine | 2003 |
Renal salt wasting without cerebral disease: diagnostic value of urate determinations in hyponatremia.
Topics: Aged; Female; Hip Fractures; Humans; Hyponatremia; Inappropriate ADH Syndrome; Kidney; Uric Acid | 2007 |